ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1354 National Cancer Institute Html null Melanoma Treatment (PDQ®)–Patient Version Expert-reviewed information summary about the treatment of melanoma.
CLICK HERE
1465 National Cancer Institute Html en Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Health Professional Version Expert-reviewed information summary about the treatment of childhood acute myeloid leukemia, myelodysplastic syndromes, and other myeloproliferative disorders.
cytogenetically normal AML0.472151
acute myelogenous leukemia0.566998
acute myeloid leukemias0.479592
acute leukemia cells0.490369
Mixed-phenotype acute leukemia0.492893
pediatric AML chromosomal0.458451
acute leukemias0.458907
mutations0.522652
myeloid leukemia patients0.500607
leukemia group0.471134
biphenotypic acute leukemia0.49298
children0.465
pediatric myeloid leukemia0.49349
childhood AML0.456416
chronic myelomonocytic leukemia0.469481
AML0.543947
World Health Organization0.492048
CEBPA mutations0.477251
leukemia development0.468848
acute monocytic leukemia0.483805
chronic myelogenous leukemia0.468404
Acute myelomonocytic leukemia0.489711
prognostic significance0.496134
international retrospective study0.454979
promyelocytic leukemia cases0.462082
pediatric leukemia0.454781
pediatric AML patients0.456596
et al.0.655126
acute megakaryoblastic leukemia0.509773
normal pediatric AML0.45551
myeloid neoplasms0.47963
internal tandem duplication0.460861
Br J Haematol0.501425
acute promyelocytic leukaemia0.457345
normal myeloid development0.457734
acute myeloid leukemia0.996934
acute myeloid leukaemia0.513022
Leukemia Study Group0.464981
juvenile myelomonocytic leukemia0.495899
myeloid leukemia cells0.495298
acute megakaryocytic leukemia0.484055
mixed lineage leukemia0.460628
Abstract0.599778
Clin Oncol0.480965
AML patients0.464901
blood0.501248
promyelocytic leukemia correlates0.463064
acute promyelocytic leukemia0.625964
pediatric AML0.496596
CLICK HERE
1506 National Cancer Institute Html en Uterine Sarcoma Treatment (PDQ®)–Health Professional Version Expert-reviewed information summary about the treatment of uterine sarcomas.
carcinosarcomas0.527692
preceding study0.294778
ongoing clinical trial0.328334
higher response rate0.443879
second-line therapy0.320988
GOG-87B trial0.302772
combination arm0.302761
parallel endometrial cancer0.512209
antitumor activity0.3101
overall survival0.306973
wrong pathology0.309304
randomized comparison0.315064
combination0.391895
GOG-108 trial0.299664
patients0.983458
response rate0.846539
toxic 5-day regimen0.481752
epidemiologic features0.339925
recurrent disease0.339729
endometrial stromal cell0.349768
homologous elements0.328462
Gynecologic Oncology Group0.655599
stromal components0.337885
prior radiation therapy0.439727
radiation therapy0.469225
evaluable patients0.303784
vs0.355238
study0.345019
postmenopausal predominance0.341262
longer progression-free survival0.464996
heterologous elements0.32327
Carcinosarcomas parallel endometrial0.494212
stromal cell sarcomas0.343743
endometrial adenocarcinomas0.337476
separate trials0.29781
cisplatin0.316026
first-line therapy0.436639
significant improvement0.309111
uterine sarcoma0.513207
therapy0.475954
follow-up GOG-01610.313043
response rates0.291195
chemotherapy studies0.29709
modality approaches0.330804
partial response rate0.446598
uterine sarcomas0.312583
hazard ratio0.311967
confidence interval0.314154
striated muscle0.341592
CLICK HERE
1745 National Cancer Institute Html en Radon and Cancer A fact sheet about radon, an odorless radioactive gas, and its possible association with cancer, and how to test for radon in the home.
residential radon0.562353
American case-control studies0.256996
lung cancer0.983232
radon test kit0.445489
homes0.263005
tiny radioactive particles0.260576
radon risk0.437726
indoor radon levels0.492199
Lubin JH0.260179
lung tumors0.286182
long-term tests0.254643
residential radon exposure0.479323
average radon level0.4525
slightly increased risk0.263122
experimental animal studies0.260434
radon gas0.490329
radon programs0.421637
radon exposure0.485254
Environmental Protection Agency0.303434
National Radon Hotline0.443169
Radon Reduction0.421521
radon testing0.473889
radon0.847228
National Radon0.44518
United States0.325125
radon causes lung0.520748
radioactive gas0.261736
high radon levels0.476793
U.S. Environmental Protection0.30233
underground uranium miners0.261056
radon mitigation promotion0.443958
normal decay0.26025
low levels outdoors0.269932
radon studies0.441219
highest radon levels0.486865
German uranium miners0.256763
different indoor radon0.45539
radioactive particles0.292648
radon levels0.737469
Health Physics0.256943
Radon Program Services0.446453
radon-related cancer deaths0.313801
lung cancer deaths0.435124
lung cancer risk0.337519
local radon official0.450897
elements uranium0.296591
National Radon Hotlines0.444919
et al0.254717
CLICK HERE
1872 National Cancer Institute Html es Tratamiento del cáncer de células de transición de pelvis renal y de uréter (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento del cáncer de células de transición de pelvis renal y de uréter.
Compton CC0.310067
prognostic factors0.311079
Roth BJ0.353197
transitional cell carcinoma0.558604
Sin embargo0.332107
Ta Carcinoma0.313126
Elson PJ0.309122
California Oncology Group0.314515
7th ed0.310032
tumores renales0.309511
pelvis renal0.960657
Instituto Nacional0.312591
metástasis distantes0.32208
células transicionales recidivantes0.361913
pared pélvica renal0.316324
parénquima renal t30.317938
cooperative group study0.316918
Cooperative Oncology Group0.315511
tejido renal0.313083
metastatic transitional cell0.319135
preliminary report from0.31524
group study0.325781
Einhorn LH0.327583
urinary tract0.331593
función renal0.325386
Northern California Oncology0.31495
upper urinary tract0.318654
effective chemotherapy regimen0.317306
Oncology Group study0.317114
Nocks BN0.30983
Cancer Staging Manual0.321607
PDQ Tratamiento0.309071
Renal pelvic tumors0.315825
New York0.30907
Daly JJ0.308968
with paclitaxel0.310585
Clin Oncol0.437926
parénquima renal0.327814
Byrd DR0.309554
urothelial carcinoma0.398878
gallium combination chemotherapy0.316792
insuficiencia renal0.313531
Eastern Cooperative Oncology0.315974
renal pelvis0.422209
Oncology Group0.324511
Tis Carcinoma0.313191
metastatic urothelial carcinoma0.363244
AJCC Cancer Staging0.322547
Edge SB0.31008
CLICK HERE
1962 National Cancer Institute Html es Tratamiento de las neoplasias mielodisplásicas o mieloproliferativas (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mielodisplásicas o mieloproliferativas, incluso las leucemias mielomonocíticas crónicas o juveniles, y la LMC atípica.
siguientes procedimientos0.310473
células madre0.796441
cuidado médico0.302013
leucemia aguda0.308416
células madre formadoras0.309431
hueso compacto0.314757
enlace drugs approved0.312251
cromosoma filadelfia0.309322
célula madre mieloide0.313237
células anormales.ampliar aspiración0.315092
National Cancer Institute0.302184
siguientes riesgos0.301804
leucemia mielomonocítica0.520866
Instituto Nacional0.307834
célula madre linfoide0.331173
PDQ Tratamiento0.305968
neurofibromatosis tipo0.303576
células madre mieloide0.322767
leucemia mielógena0.392932
neoplasias mielodisplásicas0.970229
Physician Data Query0.30823
neoplasia mielodisplásica0.36973
Myeloproliferative Neoplasms0.306895
siguientes enlaces0.302219
célula madre0.398378
células sanguíneas maduras0.374442
neoplasias mieloproliferativas0.31703
ósea elabora células0.32181
siguientes pruebas0.312083
siguientes sumarios0.307642
CLICK HERE
3431 National Cancer Institute Html es Dietilestilbestrol (DES) y el cáncer Hoja informativa sobre el DES (una versión sintética del estrógeno) y los problemas de salud en los niños que estuvieron expuestos al DES en la matriz.
hormona femenina estrógeno0.312636
Hatch EE0.454515
DES problemas0.383286
Urogenital abnormalities0.305699
Diethylstilbestrol contraindicated0.311242
exposed to diethylstilbestrol0.406175
Cell Cancer Registry0.312383
British Journal0.315496
defectos congénitos0.317789
reproductive characteristics0.305946
Noller KL0.315866
related synthetic hormones0.309521
Prenatal diethylstilbestrol0.312976
diethylstilbestrol during pregnancy0.315088
Environmental Health0.313238
posibles efectos0.334954
Internal Medicine0.305939
Estados Unidos0.328505
DES Follow-up Study0.443119
abortos espontáneos0.319323
NCI Mamografías0.30661
resultados contradictorios0.314367
long-term health effects0.309445
PubMed Abstract0.959102
International Journal0.31496
Cancer Control0.307472
Carcinogénesis Hormonal Transplacentaria0.310163
DES daughters0.375119
given diethylstilbestrol0.321239
cohort study0.315559
Titus-Ernstoff L0.382214
Hormonal Transplacental Carcinogenesis0.31001
mayores riesgos0.313929
Environmental Health Sciences0.309128
Troisi R0.359524
Hoover RN0.313827
stilbestrol therapy with0.308895
FDA Drug Bulletin0.308403
to diethylstilbestrol alters0.318831
Verloop J0.312608
cuello uterino0.526442
Public Relations Committee0.308493
exposed prenatally0.313265
to des0.379155
riesgos instantáneos porcentaje0.310067
menopausia prematura0.316803
to diethylstilbestrol0.546373
New England Journal0.327355
DES Porcentaje0.382487
CLICK HERE
3451 National Cancer Institute Html en Planning the Transition to End-of-Life Care in Advanced Cancer (PDQ®)–Patient Version Expert-reviewed information summary about the preparation needed by health care providers, patients, and families for the transition to end-of-life care in advanced cancer.
CPR0.551685
end-of-life decisions0.505947
treatments0.539675
PDQ cancer information0.625539
Out-of-hospital DNR order0.511763
health care team0.497649
clinical trials0.511926
wishes0.516111
health care providers0.549541
emergency medical workers0.548212
cancer information summary0.569329
health care professionals0.505787
family members0.526957
patients0.489953
end-of-life care options0.519094
symptoms0.496271
NCI PDQ cancer0.514682
new chemotherapy treatment0.48923
doctors0.602249
supportive care0.525701
life-saving procedures0.497748
care0.924816
end-of-life care0.782032
treatment0.671878
DNR order0.576468
Palliative Care Organization0.500652
breathing stops0.496404
palliative care0.693314
Cancer Information Service0.494158
Health care proxy0.49362
cardiopulmonary resuscitation0.54384
hospice care0.526131
National Cancer Institute0.571506
decisions0.647069
Advance directives0.611485
health care0.652677
Palliative Care Editorial0.541845
advanced cancer0.542943
Cancer Care page0.510244
Care Editorial Board0.540113
PDQ summary0.57393
doctor0.567646
end stages0.495403
breathing machine0.491509
cancer information summaries0.492454
comprehensive cancer information0.492895
cancer0.776389
information0.649786
CLICK HERE
3526 National Cancer Institute Html es Dosis altas de vitamina C (PDQ®)–Versión para pacientes Resumen de información revisada por expertos sobre el uso de dosis altas de vitamina C como tratamiento para personas con cáncer.
cuerpo capta0.40884
Centro Nacional0.415435
trastornos renales0.409265
New Hampshire Avenue0.4108
voluntarios sanos0.40968
Drug Administration0.406678
NCI Best Case0.417317
vía oral0.410816
datos bibliográficos pubmed0.411428
Ewan Cameron0.409689
siguientes preguntas0.406272
modelo murino0.409716
PDQ Dosis0.435611
químico linus pauling0.417313
vitamina c0.94266
National Cancer Institute0.412764
siguientes riesgos0.407804
Instituto Nacional0.459849
quimio terapia0.40979
premio nobel0.409373
Salud Complementaria0.42125
medicamento bortezomib0.415099
Visuals Online0.407849
complementarias revisa0.410331
pequeñas cantidades0.408757
Physician Data Query0.445061
Estados Unidos0.504589
cálculos renales0.409375
libre uso0.407317
cabo estudios0.435571
claro cuánto0.409653
página manejo0.407381
¿El tratamiento0.414934
¿Los beneficios0.406643
juntos cam0.406416
Series Program0.406643
medicina complementaria0.607291
CLICK HERE
3606 National Cancer Institute Html en Bioinformatics and Cancer Researchers take on challenges and opportunities to mine
analytical tools0.503896
data0.930485
complex biological questions0.5412
computational tools0.425959
research0.765612
research program0.461031
precision medicine—that0.427901
Cancer Informatics Program0.53792
primary data0.493101
research community0.640856
comprehensive molecular analyses0.497733
cancer research data0.639487
researchers0.498144
molecular characteristics0.432662
Big Data0.513141
NCI’s Center0.486223
NCI-funded studies0.438225
NCIP Hub0.491716
commercial cloud providers0.498944
cloud technology0.483618
Genome Research Institute0.551547
cancer research community0.589113
access0.431106
numerous research areas0.554113
imaging studies0.432684
NCI-funded research0.466881
cancer research0.762444
healthy tissue samples0.490086
data clouds0.491108
NCI’s TARGET0.476821
TCGA-collected data0.483444
Genomic Data Sharing0.579305
molecular data0.478795
multi-investigator research teams0.550054
different technological platforms0.513272
studies0.49641
translational studies0.42911
sheer volume0.427853
NCI Cancer Genomics0.60107
cancer researchers0.462047
cancer genomics repository0.530232
biological data0.643746
clinical care0.431785
different tools0.428018
Cancer Genome Atlas0.527253
biomedical research0.47962
cancer research projects0.699979
potential new targets0.495536
NCI Genomic Data0.63374
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.